PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales